LAVA Therapeutics NV (LVTX)

2.52 -0.06 (-2.33%)
Close USD Disclaimer

LAVA Therapeutics NV Company Profile

Equity Type
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Contact Information
Utrecht,3584 CM Netherlands
31 630 00 30 35
Top Executives
Kapil Dhingra 62 2021 Non-Executive Chairman
Stephen Allen Hurly 54 2019 CEO, President & Executive Director
Andrea van Elsas 56 2018 Chairman of Advisory Board
Stefan Luzi 38 2018 Non-Executive Director
Padmanee Sharma 0 2020 Member of Advisory Board
Karen J. Wilson 59 2021 Independent Non-Executive Director
Dane Wittrup 0 0000 Member of Advisory Board
Madhav V. Dhodapkar 0 0000 Member of Advisory Board
Dieter Kabelitz 0 0000 Member of Advisory Board
James Julian Noble 63 2022 Non-Executive Director
James Patrick Allison 0 2020 Member of Advisory Board
Guido Magni 69 2018 Independent Non-Executive Director
Jay T. Backstrom 67 2022 Non-Executive Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles